First participant imaged in Phase II SAR-Bombesin trial
Filed with ASX · · 3 pages · English
Clarity Pharmaceuticals (ASX: CU6) (“Clarity”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce 64 it has successfully imaged its first participant in the US-based diagnostic Cu SAR-Bombesin trial (SABRE 1 NCT05407311) for patients with PSMA-negative prostate
Clarity Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Clarity Pharmaceuticals
- First participants imaged in SAR-Bombesin trial
- Recruitment opens for Phase II trial in Prostate Cancer
- Paediatric neuroblastoma trial advances to cohort 3
- Imaging trial in prostate cancer opens for recruitment
- Application for quotation of securities - CU6
Later from Clarity Pharmaceuticals
- First patient treated in therapeutic prostate cancer trial
- 50% recruitment milestone reached for prostate cancer trial
- Corporate Presentation - Wilsons Drug and Device Conference
- 50% recruitment reached for Phase II prostate cancer trial
- Clarity Presentation -Bell Potter Healthcare Conference 2022
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals